CJC-1295 + ipamorelin blend
CJC-1295 with ipamorelin is the most widely sold growth-hormone peptide pairing. Each part raises growth hormone in short studies. No trial has tested them together, and neither can be legally compounded in the US.
- Legal lane: not FDA-approved. Neither ingredient is eligible for pharmacy compounding.
- Evidence grade: D for the combination. Each ingredient alone is graded C.
- Form: injection under the skin, sold premixed or as two vials
- Sport: both ingredients are prohibited
What it is
Two peptides that push the pituitary to release growth hormone by different routes. CJC-1295 is a synthetic version of growth-hormone-releasing hormone. Ipamorelin imitates ghrelin at the receptor that triggers a growth hormone pulse. Sellers pair them on the theory that two signals produce a bigger release than one.
"CJC-1295" covers two different products. The form with DAC lasts about six to eight days. The form without DAC is short-acting and largely unstudied. Blends rarely say clearly which one they contain.
What the evidence shows
No human trial has tested the combination.
- CJC-1295: two placebo-controlled trials published in 2006 found that one injection of the DAC form kept growth hormone raised for six days or more. No trial has shown a benefit for muscle, fat loss, recovery or aging.
- Ipamorelin: short studies show a brief growth hormone pulse. Its one Phase 2 trial, for bowel recovery after surgery, did not meet its main goal, and development stopped.
So the pairing rests on hormone measurements from each part alone. Nobody has measured what people buy it for.
Legal status
- CJC-1295: not FDA-approved and not on the list of substances pharmacies may compound. An FDA advisory committee recommended against adding it.
- Ipamorelin: in October 2024 an FDA advisory committee voted 0 to 12, with one abstention, against adding it to that list.
- Neither was part of the October 2026 policy, which also allows only one active ingredient per product.
Some clinic websites say ipamorelin was "reinstated" in 2026. We could not confirm that from FDA records.
Reported dosing
No dose has been established for this combination.
No trial has tested the pair, and clinical development of both ingredients ended before an approved dose was set for either. The figures that circulate for each ingredient, and where they come from, are on the CJC-1295 and ipamorelin pages.
Safety
- Long-term effects of keeping growth hormone raised this way have not been studied for either ingredient, alone or together.
- With a premixed vial you cannot tell which ingredient caused a reaction.
- Products bought outside a pharmacy have no verified contents or sterility, and the form of CJC-1295 in the vial is often unclear.
Common questions
Has CJC-1295 with ipamorelin been tested together?
No. No human trial has tested the combination.
Is the CJC-1295 and ipamorelin blend legal?
Neither ingredient is FDA-approved or eligible for pharmacy compounding, and neither was part of the October 2026 policy.
Why are they sold together?
They trigger growth hormone release by different routes, and sellers expect the two signals to add up. That expectation has not been tested in a trial.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- Teichman et al., 2006: CJC-1295 Phase 1 trials (PubMed)
- Beck et al. 2014: randomized trial of ipamorelin for postoperative ileus (PubMed)
- FDA briefing document: CJC-1295-related bulk drug substances (December 2024)
- FDA briefing document: ipamorelin-related bulk drug substances (October 2024)
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
- HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition